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Alterations in the tumour suppressor p53 have been reported in tumour-associated stromal cells; however, the consequence of
these alterations has not been elucidated. We investigated p53 status and responses to p53-activating drugs using tumour-associated
stromal cells from A375 melanoma and PC3 prostate carcinoma xenografts, and a spontaneous prostate tumour model (TRAMP).
p53 accumulation after treatment with different p53-activating drugs was diminished in tumour-associated stromal cells compared to
normal stromal cells. Tumour-associated stromal cells were also less sensitive to p53-activating drugs – this effect could be
reproduced in normal stromal cells by p53 knockdown. Unlike normal stromal cells, tumour stromal cells failed to arrest in G2 after
etoposide treatment, failed to upregulate p53-inducible genes, and failed to undergo apoptosis after treatment with vincristine. The
lower levels of p53 in tumour stromal cells accompanied abnormal karyotypes and multiple centrosomes. Impaired p53 function in
tumour stroma might be related to genomic instability and could enable stromal cell survival in the destabilising tumour
microenvironment.
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Both cancer and healing wounds are characterised by increased
proliferation and infiltration of endothelial cells, inflammatory
cells, and fibroblasts (Dvorak, 1986). These infiltrating stromal
cells (SC) may by tissue-resident and/or bone marrow-derived and
together constitute the stromal microenvironment. The function of
SC in tumours and physiological wound healing is to secrete
matrix proteins and factors involved in tissue remodelling and to
secrete chemotactic factors for inflammatory cells and endothelial
cells. Thus, both tissue injury and cancer resemble an ‘activated’
state whereby the host’s response is designed to heal the affected
tissue (Coussens and Werb, 2002).
The tumour microenvironment consists of tumour cells, SC, and
the matrix proteins, growth factors, and cytokines they produce
(Liotta and Kohn, 2001). Fibroblasts comprise the majority of the
tumour stroma, and their role in tumours is long-recognised
(Seemayer et al, 1979). For example, fibroblasts are responsible for
the synthesis of fibronectin and types I, III, and V collagens that
make up basement membranes; they also secrete factors such as
TGF-b that support nonautonomous tumour epithelial growth
(Tlsty, 2001; Bhowmick et al, 2004). Functionally and phenotypi-
cally distinct myofibroblasts are also observed in most tumours
(Sappino et al, 1988). Myofibroblasts express a-smooth muscle
actin (a-SMA), which enhances their contractility and motility
(Hinz et al, 2007), and they overexpress stromal-derived factor,
which mobilises bone marrow-derived endothelial progenitor cells
(Orimo et al, 2005).
Owing to genomic instability, cancer cells are typically mutable
and develop drug resistance; thus, targeting SC in the tumour
microenvironment may be a viable approach for helping to eliminate
solid tumours (e.g., antiangiogenesis). However, it has recently
become clear that like tumour cells, tumour-associated SC may be
characterised by genomic instability and p53 mutations (Kurose
et al, 2002; Hill et al, 2005). For example, numerous genetic
amplifications and deletions were detected in murine stromal DNA
isolated from implanted tumour xenografts (Pelham et al, 2006).
Furthermore, cytogenetic (Moinfar et al, 2000; Allinen et al,2 0 0 4 ;
Fukino et al, 2004; Hida et al, 2004) and epigenetic (Kaplan et al,
2005) alterations have been described in tumour stroma and in tissue
adjacent to carcinoma (Deng et al, 1994). The possibility that
cytogenetic alterations in tumour SC including p53 mutations might
accompany changes in p53 function has not been addressed.
In cancer cells, the principal cause of resistance to chemother-
apeutic drugs is chromosomal instability accompanied by deletion
of or mutations in p53; however, both drug resistance and
increased sensitivity in a p53 null background have been noted
(Bunz et al, 1999; Burdelya et al, 2006). p53 is mutated or lost in
about half of all cancers probably as a consequence of selection
pressure for p53 mutations, which enable tumour cell survival
(Gorgoulis et al, 2005). The importance of functional p53 in
tumours has been formally proven by reintroduction of wild-type
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sp53 in tumour cells in vivo (Martins et al, 2006; Ventura et al,
2007). However, it has been noted that re-imposition of p53
function was quickly mitigated by p53 inactivation and the
emergence of p53-resistant tumours (Martins et al, 2006). Despite
these detailed studies investigating p53 function in tumour cells,
no studies to date have examined the relationship between p53
status and sensitivity to cytotoxic DNA-damaging agents in
tumour-associated SC.
In this report, we show that tumour SC, in contrast to normal
SC, fail to undergo growth arrest and apoptosis after treatment
with etoposide or vincristine, respectively. Tumour SC show
diminished p53 expression, and p53 fails to or only marginally
accumulates after treatment with p53-activating stimuli. Tumour
SC also have multiple centrosomes and are aneuploid – both of
which are readouts of abnormal p53 function. Together, these results
indicate that, similar to tumour cells, alterations in p53 function and
decreased sensitivity to commonly used p53-activating chemo-
therapeutic drugs are features of tumour-associated SC.
MATERIALS AND METHODS
Cell lines and media
All primary cells were cultured in EGM2-MV medium (Cambrex
Bioscience, Rockland, ME, USA) and were maintained in an
atmosphere of 5% CO2 at 371C. PC3MLN4 prostate carcinoma cells
were grown in HAMS with 10% FBS, and A375SM melanoma cells
were grown in MEM with 10% FBS. Tumour cells were grown
under 10% CO2. Normal and tumour SC were obtained from
isolated endothelial cultures overtaken by rapidly growing
fibroblast-like cells. This was a common occurrence in our hands,
and was unavoidable without strict monitoring of the pure
endothelial cultures (Hida et al, 2004).
Mice
All animal procedures were performed in compliance with Boston
Children’s Hospital Guidelines and were approved by the
Institutional Animal Use and Care Committee. The procedures
for cell isolation for A375 tumour xenografts were previously
described (Hida et al, 2004). For the PC3MLN4 prostate
carcinoma, one million cells were injected subcutaneously into
the dorsal lateral flank of 8-week-old nu/nu mice. When tumours
reached 1cm
3 (approximately 4–6 weeks postimplantation),
tumours were harvested as described by Hida et al (2004).
Tumours from five mice were combined for the cell isolation.
TRAMP mice were genotyped at 4 weeks of age (Transnetyx,
Cordova, TN, USA) and tumours were harvested when mice
reached 20–22 weeks.
Antibodies and reagents
The mouse monoclonal p53 and rabbit polyclonal pSER15 and
pSER20 p53 antibodies were purchased from Cell Signaling
Technologies (Danvers, MA, USA). b-actin, caldesmon, a-SMA,
and fibroblast-specific protein-1 (FSP-1) antibodies were from
Sigma-Aldrich (St Louis, MO, USA). The CD105 antibody was from
BD Pharmingen (San Jose, CA, USA). Rabbit polyclonal pericentrin
antibody was from Covance (Berkeley, CA, USA). Etoposide and
vincristine were dissolved in DMSO and were purchased from
Sigma-Aldrich.
Drug treatment
To analyse p53 expression, cells were seeded at a density of 200000
cells per 10cm
2 and left overnight. The next day, the indicated
drug was added, and the cells were incubated between 8 and 24h.
Cell lysates were prepared in RIPA buffer and subjected to western
blotting according to standard methods. Nuclear fractions were
prepared using the NE-PER kit according to the manufacturer
(Pierce, Rockford, IL, USA). For viability studies, cells were seeded
at 2500 cells per well in a 96-well plate. The next day, the indicated
concentration of each drug was added, and the cells were
incubated for an additional 72h. Cell counts were determined by
dispersing the cells in trypsin and counted using a Coulter counter
(Beckman Coulter, Fullerton, CA, USA; Model Z1).
Fluorescence-activated cell sorting
Fluorescence-activated cell sorting (FACS) for cell characterisation
was carried out on live cells used between 6 and 10 passages.
Propidium iodide and annexin V staining were done according to
the manufacturer’s instructions (BD Pharmingen). Cells were
analysed on a BD FACSCalibur System.
Immunofluorescence
Cells were seeded at a density of 10000 cells per well in gelatin-
coated eight-well chamber slides. Confluent cells were washed
twice with PBS and then fixed with ice-cold 100% methanol at
 201C for 20min. The fixed cells were rinsed briefly with PBS and
then blocked for 1hour at room temperature with PBS containing
5% BSA. After blocking, antibodies were added overnight at 41Ci n
a humidified chamber. The next day, cells were rinsed with PBS
and then blocked again for 30min at room temperature. Secondary
antibodies were added and the cells were incubated an additional
hour at room temperature protected from light. Finally, the cells
were washed with PBS and then mounted using Gel Mount
(Biomeda, Foster City, CA, USA) containing 0.4mgml
 1
40,6-diamidino-2-phenylindole.
p53 sequencing
cDNA was prepared from normal and tumour SC by reverse
transcription. Primers specific for the mouse p53-coding regions
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Figure 1 Stromal cell characterisation. (A) Morphology of SC from
normal mouse skin or subcutaneous xenografts of A375 melanoma (a) and
comparison of their growth properties in culture (b). (B) By immuno-
fluorescence, SC stained uniformly positive for caldesmon, CD105, and
FSP-1. a-SMA was expressed only in the tumour SC, indicative of a
myofibroblast-like phenotype.
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swere used to amplify a 1173bp fragment that was subcloned into
the PCR-2 vector (Invitrogen, Carlsbad, CA, USA). Plasmid DNA
was cloned in Top10 cells, purified, and sequenced using the same
primers for PCR amplification. Sequences were analysed using
Chromas software.
Karyotyping
Karyotyping was carried out by the Brigham and Women’s
Cytogenetics Core Facility, Boston, MA, USA.
siRNA
Mouse siRNA for p53 was purchased from Dharmacon (Lafayette,
CO, USA). Cells were transfected using Silentfect transfection
reagent according to the manufacturer’s instructions (BioRad,
Hercules, CA, USA).
RESULTS
Stromal cell characterisation
Previously, our laboratory identified cytogenetic alterations in
tumour-specific endothelial cells (Hida et al, 2004). In the present
study, we found that isolates of endothelial cells from A375
melanoma were frequently overtaken by fibroblast-like stromal
cells (MeSC), which grew on average two to three times the rate of
normal SC from mouse skin (SkSC) (Figure 1A). In contrast to
tumour endothelial cells described by Hida et al (2004), these cells
were negative for the EC markers CD31 and VEGFR2 (data not
shown), but positive for caldesmon, CD105, and FSP-1 (Figure 1B).
a-Smooth muscle actin expression was restricted to the SC from
melanoma, possibly owing to their ‘activated’ or myofibroblast-
like phenotype observed in most tumours (Orimo et al, 2005). On
the basis of morphology and marker expression, the isolated SC
used in this study were identified as fibroblasts or myofibroblasts.
p53 function in normal and tumour stromal cells
Ultraviolet (UV) light causes DNA damage, which is repaired via a
p53-dependent mechanism (Nelson and Kastan, 1994). As
expected, p53 levels were increased in normal SkSC after UV
treatment (Figure 2A). Strikingly, p53 only marginally accumu-
lated in MeSC after treatment with UV light. Next, the p53
responses in SkSC or MeSC following treatment with different p53-
activating drugs were determined. Although etoposide caused an
approximate five-fold increase in p53 and SER15-phosphorylated
p53 in SkSC at all doses, only a two-fold increase in p53 was
evident in MeSC (Figure 2B). Time course experiments using
vincristine produced similar results, with a maximum seven- to
eightfold increase in p53 levels in SkSC after drug treatment and
only a one- to twofold increase in MeSC. TNP-470, a compound
not known as a p53 inducer, did not cause a remarkable
upregulation of p53 or p53 phosphorylation at any time point in
both SC.
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Figure 2 p53 function in tumour stromal cells. (A) Western blotting of
whole-cell lysates from UV-treated SkSC and MeSC. Cells were treated
with 100mJcm
 2 for 5min and lysates were prepared 6h later. (B)
Western blotting of whole-cell lysates from 8h etoposide-treated (a), 1nM
vincristine-treated (b), or 10mgml
 1 TNP-470-treated cells (c). The same
blots were stripped and re-probed with rabbit polyclonal pSER15 p53
antibodies and then mouse monoclonal b-actin antibodies. (C) Dose–
response curves for etoposide (a), vincristine (b), and TNP-470 (c). Cells
were plated in triplicate and treated with each drug for 72h before
dispersing in trypsin and counting. *Results are statistically significant
(Po0.05) by student’s t-test.
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Figure 3 p53 knockdown in SkSC decreases sensitivity to etoposide and
vincristine. (A) p53 knockdown was complete at the RNA (a) and protein
levels (b) using siRNA. (B) p53 knockdown resulted in multiple less-
uniform centrosomes (a), and about 30% of the cells had an abnormal 42
pericentrin signals per cell (b). (C) Cell numbers determined in p53
knockdown SkSC after a 72h treatment with etoposide (a), vincristine (b),
and TNP-470 (c). Cells were plated in triplicate and treated with each drug
for 72h before dispersing in trypsin and counting. *Results are statistically
significant (Po0.05) by student’s t-test.
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sMeSC are less sensitive to p53-activating drugs
We compared the viability of SkSC and MeSC following treatment
with each p53-activating drug. Although both cell types were growth-
inhibited by etoposide and vincristine, MeSC were consistently less
sensitive when compared to SkSC. In contrast, no difference in
viability was seen in SkSC or MeSC treated with TNP-470, which also
did not upregulate p53 (Figure 2C). To confirm a p53-specific effect,
we knocked down p53 in SkSC using p53 siRNA. p53 knockdown
was complete at the RNA and protein levels (Figure 3A). As a
readout of p53 function, we measured centrosome numbers in SkSC
after p53 knockdown (Bennett et al, 2004). p53 knockdown in SkSC
resulted in multiple centrosomes per cell, consistent with the role of
p53 in regulating centrosome duplication (Figure 3B). Furthermore,
the dose–response curves for etoposide and vincristine showed that
p53 knockdown rendered SkSC less sensitive to each drug
(Figure 3C). No change in sensitivity to TNP-470 was observed,
consistent with the failure of TNP-470 to activate p53.
p53 localises to the nucleus in MeSC but the total cellular
p53 pool is reduced
As p53 mutations may result in its sequestration in cytoplasm or
nucleus, we determined the subcellular localisation of p53 by
immunofluorescence and cell fractionation studies. By immuno-
fluorescence, p53 localised predominately to the nucleus in
both SkSC and MeSC in untreated cells and in cells treated with
etoposide (Figure 4A). However, when the results were
quantified, nuclear p53 levels in SkSC treated with etoposide or
vincristine were approximately twofold higher compared to MeSC
(Figure 4B). Western blotting of purified nuclear and cytosolic
extracts of etoposide-treated cells confirmed that p53 was
predominately localised to the nucleus, where it was strikingly
increased in SkSC, but not MeSC (Figure 4C). It is worth noting
that almost 10 times as many cells with endoduplicated nuclei
(nuclear division without cell division) were detected in MeSC
compared to SkSC after vincristine treatment (Figure 4D).
Endoduplication is commonly observed in p53-null mouse
embryonic fibroblasts treated with microtubule inhibitors and
occurs due to checkpoint failure in the absence of normal p53
function (Lanni and Jacks, 1998).
MeSC fail to arrest in G2 after etoposide treatment
As the growth inhibitory effects of etoposide are mainly due to G2
arrest, cell cycle status in etoposide-treated cells was determined
by propidium iodide (PI) staining followed by FACS. In SkSC
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Figure 4 p53 localises to the nucleus in SkSC and MeSC, but the total cellular p53 pool is reduced. (A) p53 immunofluorescence in SkSC and MeSC
treated with etoposide (10mM, 8h). Note the predominant nuclear staining for p53 in both the cell types, although the p53 signal in MeSC is diminished.
(B) The luminosity for the nuclear p53 signal in treated and untreated cells was measured in 10 cells from three random fields and plotted. (C) Western
blots of purified nuclear and cytoplasmic fractions from etoposide-treated cells (10mM, 8h). As loading controls, blots were stripped and re-probed with
g-tubulin (cytoplasm) and lamin A/C (nucleus). (D) Vincristine-treated cells (1nM, 24h) were methanol-fixed, and the nuclei stained with DAPI. The circled
cells are single cells, and the arrows point to endoduplicated nuclei (a). Cells in 10 random fields were counted, and the average number of cells with
multiple nuclei (43 per cell) was plotted (b).
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streated with etoposide, the number of cells in G2 almost doubled
compared to untreated cells. In contrast, MeSC failed to
accumulate in G2 (Figure 5A and B). By semiquantitative
RT–PCR, the expression of p53-inducible genes related to cell
cycle arrest and apoptosis including PUMA, Bax, and p21 was
upregulated in SkSC, but not in MeSC after etoposide treatment
(Figure 5C). Notably, the constitutive levels of these genes were
also qualitatively lower in MeSC relative to SkSC. No differences in
p53 or in the negative regulator of p53 stability, MDM2, were
detected. Taken together, these results were consistent with a failed
induction of p53 and p53-inducible genes related to apoptosis or
cell cycle arrest in MeSC after etoposide treatment.
MeSC fail to undergo apoptosis after vincristine treatment
Dual staining using PI and annexin V (AV) in vincristine-treated
cells indicated an increase in AV
þ/PI
þ cells in SkSC, but not
MeSC (Figure 6A). The number of early apoptotic AV
þ cells
increased six times above untreated cells in SkSC but only two
times in MeSC (Figure 6B). Thus, the decreased sensitivity to
vincristine in MeSC relative to SkSC was most likely due to
decreased p53-dependent apoptosis.
p53 function is impaired in stromal cells from PC3 and
TRAMP prostate tumours
To determine if SC from different tumours also showed diminished
p53 function, we isolated SC from PC3 xenografts and spontaneous
prostate tumours in TRAMP mice. Both PC3SC and TRAMPSC had
a fibroblast-like morphology, were negative for EC markers (data
not shown), and were positive for FSP-1, indicating that they were
tumour-associated fibroblasts, similar to SC from A375 melanoma
(Figure 7A). For all tumour xenografts used in this study,
diphtheria toxin was used to eliminate human tumour cells from
cultures (Arbiser et al, 1999). Diphtheria toxin could not be used in
the TRAMP model because these are spontaneous tumours with no
human component. However, TRAMPSC did not express epithe-
lial-specific E-cadherin by FACS or immunofluorescence, indicat-
ing absence of contaminating tumour cells (data not shown).
Similar to MeSC, both PC3SC and TRAMPSC showed only modest
increases in p53 after treatment with etoposide or vincristine,
whereas p53 levels in SkSC were markedly upregulated (Figure 7B).
Both vincristine and etoposide treatment increased SER15
phosphorylation in both normal and tumour SC, although the
levels were reduced in tumour SC presumably due to the decrease
in total p53 levels. However, although SER20 was phosphorylated
in normal SC after vincristine treatment, no increase in SER20
phosphorylation was evident in tumour SC. No SER20 phosphor-
ylation was detected in SkSC or PC3SC after treatment with
etoposide (data not shown). Similar to MeSC, and in good accord
with the diminished p53 levels, TRAMPSC and PC3SC were less
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Figure 6 MeSC fail to undergo apoptosis after vincristine treatment. (A)
Cells treated with 1nM vincristine for 24h were double stained with PI and
AV and analysed by FACS. An increase in PI
þ/AV
þ and PI
 /AV
þ cells was
detected in vincristine-treated SkSC compared to MeSC. (B) The average
numbers of early apoptotic AV
þ cells from two experiments were plotted.
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ssensitive to etoposide and vincristine compared to SkSC
(Figure 7C). These results suggest that tumour-associated SC from
different tumour types show diminished p53 protein levels and
impaired p53 function.
Tumour stromal cells have multiple centrosomes and
aneuploid karyotypes
Hida et al (2004) recently reported abnormal centrosomes and
abnormal karyotypes in tumour-specific endothelial cells. About
30% of MeSC, TRAMPSC, and PC3SC also had abnormal multiple
centrosomes by pericentrin staining (Figure 8A). Karyotypes on
the isolated cells showed that all tumour SC had heterogeneous
aneuploid chromosomes whereas SkSC were normal (Figure 8B).
Taken together, SC from different types of tumours (melanoma vs
prostate) and different models (xenograft vs spontaneous) are
characterised by aneuploid karyotypes and multiple centrosomes.
DISCUSSION
Our study provides evidence for impaired p53 function in tumour-
associated SC. All tumour SC examined were characterised by
diminished p53 protein levels, decreased sensitivity to cytotoxic
drugs, and genomic instability indicated by multiple centrosomes
and aneuploid karyotypes. Although the nature of the p53 defect in
tumour SC is not yet clear, impaired p53 function in tumour
stroma could enable SC survival in the tumour microenvironment
and contribute to genomic instability.
Host SC can constitute a significant percentage of the total
tumour bulk as shown in GFP-SCID mice implanted with tumour
xenografts (Udagawa et al, 2006). Tumour-associated fibroblasts
or mesenchymal-like cells comprise a large portion of the tumour
stroma. Collectively, these cells might arise from tissue-resident
activated fibroblasts, tumour epithelial cells undergoing epithelial-
to-mesenchymal transition, resident stem or mesenchymal-like
cells, or bone marrow-derived progenitors. Recently, mesenchymal
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sstem cells localised to breast carcinoma were shown to increase
metastatic potency (Karnoub et al, 2007). Thus, by providing
scaffolds for tumour cells and other SC, and by producing growth
factors and chemotactic factors for inflammatory cells and vascular
progenitors, tumour SC can enable tumour growth and possibly
metastasis (Olumi et al, 1999; Bhowmick et al, 2004). Targeting
tumour SC may therefore be a viable approach for eliminating
solid tumours (Hofmeister et al, 2008).
Recently, our laboratory reported that endothelial cells from
human-to-mouse xenografts were aneuploid with centrosome
abnormalities 4–6 weeks after implantation (Hida et al, 2004).
Additional studies have confirmed both cytogenetic and epigenetic
alterations in tumour-associated SC and tissue adjacent to
carcinoma (Deng et al, 1994; Moinfar et al, 2000; Streubel et al,
2004). The mechanism(s) of these cytogenetic changes in tumour
stroma are not yet clear. One possibility is that SC and tumour cells
may fuse, as hypothesised in cases of allelic imbalance and
genomic instability in human breast stroma (Weber et al, 2006).
However, we found no evidence of human DNA in the karyotypes
of murine tumour SC from human-to-mouse xenografts. Selection
pressure for SC with diminished p53 function, and thus a survival
advantage in the tumour microenvironment, is also a possibility.
For example, nonautonomous oncogenic stress in tumour
epithelium may result in the selection of SC with LOH at the p53
locus (Lu et al, 2001; Hill et al, 2005; Kiaris et al, 2005). It is likely
that impaired p53 function in tumour SC might enable the
propagation of cells with damaged DNA due to checkpoint failure
leading to chromosomal instability.
A potential caveat related to targeting tumour SC is the loss of
function of tumour suppressor genes in the stromal compartment
(Patocs et al, 2007). Hill et al (2005) described widespread p53 loss
in tumour mesenchyme after 20–25 weeks in a prostate cancer
model. We evaluated p53 function and performed karyotypes in
TRAMPSC at 22 weeks following tumour initiation and in SC from
tumour xenografts at 4–6 weeks postimplantation. In either case,
alterations in p53 function, diminished p53 protein levels and
abnormal karyotypes were evident, irrespective of time or tumour
model. At present, we have been unable to detect mutations in the
p53-coding regions in SC, nor could we detect p53 LOH by
real-time–PCR using genomic DNA (data not shown). Although
real-time–PCR is a sensitive and well-established method to detect
LOH, heterogeneity in p53 status in the cultured tumour SC could
confound these results. Therefore, LOH may only be evident on a
cell-to-cell basis. Further studies will be needed to address the
mechanism of impaired p53 function in tumour SC in our in vitro
system and whether tumour SC can acquire drug resistance in vivo.
It is also possible that alterations in p53-interacting proteins
including the kinases responsible for p53 phosphorylation could
contribute to impaired p53 function in tumour SC. For example,
DNA damage imparts a well-characterised phosphorylation of
SER15 and SER20 in the p53 transcriptional activation domain.
Phosphorylation of these residues is thought to inhibit the
interaction of p53 with MDM2 and increase its stability (Appella
and Anderson, 2001). Although lower levels of p53 SER15
phosphorylation were evident in tumour SC in this study, this
was most likely due to the decrease in total levels of the p53
protein. On the other hand, SER20 did not appear to be
phosphorylated in tumour SC relative to normal SC after
vincristine treatment. It remains possible that in tumour SC,
alterations in pathways secondary to the stability of p53, rather
than direct alterations in p53, could impart a destabilising effect on
p53 leading to its degradation.
The idea that tumour SC can contribute to tumour growth and
perhaps metastasis is an emerging concept in cancer biology
(Karnoub et al, 2007). Though alterations in p53 in tumour SC
have been shown previously in vivo, we show that diminished p53
function accompanies genomic instability and decreased sensitiv-
ity to cytotoxic drugs.
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